Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies
Autore:
Saveanu, A; Morange-Ramos, I; Gunz, G; Dufour, H; Enjalbert, A; Jaquet, P;
Indirizzi:
Fac Med Nord, CNRS, UMR6544, Inst Federatif Jean Roche, F-13916 Marseille 20, France Fac Med Nord Marseille France 20 ean Roche, F-13916 Marseille 20, France Hop Enfants La Timone, Ctr Hosp, Serv Endocrinol, F-13385 Marseille, France Hop Enfants La Timone Marseille France F-13385 F-13385 Marseille, France Hop Enfants La Timone, Ctr Hosp, Serv Neurochirurg, F-13385 Marseille, France Hop Enfants La Timone Marseille France F-13385 F-13385 Marseille, France
Titolo Testata:
EUROPEAN JOURNAL OF ENDOCRINOLOGY
fascicolo: 1, volume: 145, anno: 2001,
pagine: 35 - 41
SICI:
0804-4643(200107)145:1<35:ALHAAP>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
NULL-CELL ADENOMAS; RECEPTOR SUBTYPES; GROWTH-HORMONE; EXPRESSION; TUMOR; INVITRO; OCTREOTIDE; TRANSCRIPTION; ONCOCYTOMAS; RELEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Jaquet, P Fac Med Nord, CNRS, UMR6544, Inst Federatif Jean Roche, Blvd Pierre Dramard, F-13916 Marseille 20, France Fac Med Nord Blvd Pierre Dramard Marseille France 20 20, France
Citazione:
A. Saveanu et al., "A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies", EUR J ENDOC, 145(1), 2001, pp. 35-41

Abstract

Objective: Evaluation of the efficiency of somatostatin analogues in the treatment of a mixed luteinizing hormone (LH)-, alpha -subunit-. prolactin (PRL)-secreting pituitary adenoma. Design: A 30-year-old woman, with amenorrhaea-galactorrhaea. presented with a pituitary macroadenoma. The endocrine evaluation showed high plasma Levels of PRL, LH, and alpha -subunit inhibited by 65%, 65% and 33% respectively under octreotide test (200 mug. s,c.). Long-term treatment with slow release (SR) lanreotide (30 mg/10 days, i.m.) restored menstrual cycles and normalized PRL values. Due to persisting supranormal levels of LH and alpha -subunit, and to the absence of tumoral shrinkage, the adenoma was resected by the transsphenoidal route. Methods: In vitro characterization of the somatostatin receptor subtypes (SSTR) expression and functionality. Real-time polymerase chain reaction wasperformed to quantify the expression of SSTR mRNAs and functionality of the SSTRs was assessed in cell culture studies with various concentrations ofnative somatostatin (SRIF-14) and of analogues preferential for SSTR2 or SSTR5. Results: This adenoma presented with high levels of SSTR2, SSTR3 and SSTR5mRNAs, as compared with a series of gonadotroph adenomas. In cell culture studies, PRL, LH and alpha -subunit were inhibited by 60%, 47% and 33% respectively by SRIF-14 at a concentration of 10 nmol/l. The SSTR2 (BIM-23197, lanreotide) and SSTR5 (BIM-23268) preferential analogues both produced a partial 21-38% inhibition of PRL, LH, and alpha -subunit release. Discussion: In this plurihormonal-secreting adenoma, the high efficacy of somatostatin analogues to inhibit PRL, LH and alpha -subunit secretion in vivo may be explained by the unusually high level of expression and by the functionality of both SSTR2 and SSTR5 receptor subtypes.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 07:05:36